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6/j.apsb.2016.09.00Abstract To establish an animal model of acute-on-chronic liver failure (ACLF) that would replicate the
pathological process of ACLF in humans, rats were administered porcine serum (PS) for 11 weeks. Liver
ﬁbrosis was determined by pathological and biochemical assessments. The animals then were injected with
D-galactosamine (D-gal) and lipopolysaccharide (LPS). The survival times of animals with cirrhosis and
ACLF were determined over 48 h. Other animals were killed at 0, 4, 8 and 12 h after administration of D-gal/
LPS. Liver injury was assessed by histopathological analysis and biochemical indices, and apoptosis was
detected by Western blot and TUNEL analysis. After PS administration for 11 weeks the serum levels of
hyaluronic acid and N-procollagen type III peptide increased signiﬁcantly, and serious ﬁbrosis and cirrhosis
was observed at weeks 10 and 11. Cirrhotic rats were injected with D-gal/LPS to induced ACLF; the rate of
mortality over 48 h was 80%. ALT and AST levels increased markedly at 4 h, but decreased signiﬁcantly at
8 and 12 h post-treatment. The total bilirubin, direct bilirubin, and total bile acids levels increased markedly
at 8 and 12 h. Clotting times, TNF-α and IL-6 levels increased signiﬁcantly, except for 12 h post-treatment.
Apoptosis, inﬂammation and necrosis were elevated as determined by hematoxylin-eosin staining and
TUNEL assays. BCL-2 levels decreased signiﬁcantly, While BAX levels increased signiﬁcantly.
Cytochrome c expression peaked at 8 h post-D-gal/LPS treatment. In conclusion, an ACLF model induced
by PS and D-gal/LPS was established and the underlying mechanisms of ACLF development were explored.
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Acute-on-chronic liver failure (ACLF) has generated increasing
attention in recent years. In 2009, the Asian Paciﬁc Association for
the Study of the Liver deﬁned ACLF as an acute hepatic insult
manifesting as jaundice and coagulopathy, becoming complicated
within 4 weeks by ascites and/or encephalopathy in a patient who
was previously diagnosed or undiagnosed chronic liver disease1.
The characteristic features of ACLF include a rapid progression,
the requirement for multiple organ supports, and a high incidence
of short- and medium-term mortality (50%–90%)2. In a large-scale
study3 conducted from 2000 to 2004 in China, 77.3% (618/799) of
patients with liver failure were diagnosed with ACLF and
cirrhosis. Among the patients with ACLF, 96.76% (598/618)
had HBV infection.
Effective treatments for ACLF are lacking4. The pathophysio-
logical background of ACLF remains poorly understood, necessi-
tating the development of optimal experimental ACLF models
with features resembling those of the human disorder. The most
widely used ACLF model is induced in rats5 and mice (Pko and
Pwt mice)6 by human serum albumin (HSA) and D-galactosamine
(D-gal)/lipopolysaccharide (LPS), which serve as reliable mimics
for the pathophysiological processes and histological character-
istics of ACLF, while the HSA-induced model shows relatively
high mortality with ﬁbrosis. Balasubramaniyan et al.7 developed
an ACLF model using a bile-duct ligation (BDL) method.
Hou et al.8 used CCL4 and D-gal/LPS to establish an ACLF
model. However, these two models are not entirely consistent with
the pathogenesis of ACLF, and the operation required for the BDL
model is difﬁcult.
In this study we developed a new rat model of ACLF based on
the method of Yang et al.9. To reduce the death rate in rats
following HSA administration, we used PS to induce chronic
immune liver cirrhosis, for which the pathogenesis was consistent
with HBV infection. Subsequent injection of D-gal and LPS
established the ACLF model. We utilized this model to explore
the characteristics and mechanisms underlying ACLF.2. Materials and methods
2.1. Experimental animals
Wistar rats weighing 120–150 g were obtained from Beijing
Weitonglihua Experimental Animal Co., Ltd. (Beijing, China).
They were housed in an environmentally controlled room
(2073 1C, 50720% humidity, 12-h light/dark cycle) with free
access to food and water. Animal care and all experimental
procedures were approved by the Animal Ethics Committee at
Chinese Academy of Medical Sciences & Peking Union Medical
College, and conducted in accordance with the health criteria for
care of laboratory animals enacted by the Beijing municipal
government.
2.2. Establishment of ACLF models
Male Wistar rats were randomly divided into 2 groups (control:
n¼10; ACLF model: n¼60). Rats in the ACLF group were
administered porcine serum (Beijing Solarbio Science
&Technology Co., Ltd., Beijing, China) intraperitoneally at a dose
of 0.5 mL twice per week for 11 weeks to generate an immune
liver ﬁbrosis model. After 11 weeks, rats with immune liverPlease cite this article as: Li Fangfang, et al. Establishment of a new acute-on
//dx.doi.org/10.1016/j.apsb.2016.09.003ﬁbrosis were injected intravenously with LPS (Sigma-Aldrich Co.,
USA) at a dose of 50 μg/kg. Thirty minutes later, D-gal (Sigma-
Aldrich Co., USA) was injected intraperitoneally at a dose of
600 mg/kg to induce acute liver failure via chronic liver cirrhosis.
The control group was administered physiological saline at the
same time points. Animals were killed at 0, 4, 8 and 12 h post-
treatment for blood and hepatic tissue collection. The remaining
rats were observed for survival time every hour for 48 h.2.3. Measurement of ﬁbrotic markers
Hepatic hydroxyproline (Hyp) levels were determined using a
hydroxyproline assay kit obtained from Nanjing Jiancheng Corp.
(Nanjing, China), according to manufacturer's instructions. Serum
levels of hyaluronic acid (HA) and N-procollagen type III peptide
(PIIINP) were assayed using an ELISA kit obtained from Beijing
Fangcheng Biotech, according to manufacturer's instructions.2.4. Ultrasound analysis
At 6, 8, and 10 weeks following porcine serum injection, ﬁve rats
were randomly selected and ultrasonography (US) was performed
to estimate the degree of ﬁbrosis. Before the day of examination,
animals were fasted overnight but were given free access to water.
Animals were anesthetized using pentobarbital sodium (50 mg/kg)
and their abdomens were shaved to reduce imaging artifacts. A
sound-conducting gel (Carbogels, Brazil) was applied and an US
examination was performed using a micro-ultrasound system
(VisualSonics, Canada). The animals were examined in the supine
position to assess the liver. The same transverse cross sections
were held constant throughout the experiments.2.5. Determination of serum biochemical indices
Blood samples were collected in tubes and centrifuged for 15 min at
3500 rpm (Sigma, USA) to collect serum. The serum levels of
alanine aminotransferase (ALT), aspartate aminotransferase (AST),
total bilirubin (TBiL), direct bilirubin (DBiL), and total bile acids
(TBA) were detected with an automatic analyzer (Toshiba, Japan)
using commercial kits (the ALT/GPT Kit, AST/GOT Kit, TBiL Kit,
and DBiL Kit) from Zhongsheng Beikong Co., Ltd. (Beijing,
China) according to manufacturer's instructions.2.6. Determination of prothrombin times (PTs)
Blood samples were collected in anticoagulant tubes containing
sodium citrate solution and centrifuged for 15 min at 3500 rpm
(Sigma, USA) to collect plasma. Clotting time was measured using
a kit obtained from Nanjing Jiancheng Corp. (Nanjing, China)
according to manufacturer's instructions.2.7. Determination of plasma ammonia levels
Blood samples were collected in anticoagulant tubes containing
heparin sodium and plasma ammonia measurements were per-
formed with a kit obtained from Nanjing Jiancheng Corp.
(Nanjing, China) by following the manufacturer's instructions.-chronic liver failure model. Acta Pharmaceutica Sinica B (2016), http:
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Blood samples were collected in tubes and centrifuged for 15 min
at 3500 rpm to collect serum. The serum levels of TNF-α and IL-6
were determined using a commercial enzyme-linked immunosor-
bent assay (ELISA) kit (Neobioscience Technology, Shenzhen,
China) following the manufacturer's instructions.
2.9. Histological examinations
Liver tissues were ﬁxed in paraformaldehyde solution. The tissue
samples were processed using parafﬁn block techniques in wax,
deparafﬁnization in xylene, and dehydration in alcohol. The
samples were then sectioned (45 μm) and stained with
hematoxylin-eosin (H&E) to evaluate the pathological changes
that had occurred in the liver. Sections were then examined by
light microscopy (Olympus, Japan).
2.10. Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assays
Portions of liver samples were embedded in parafﬁn and sliced
into sections. The sections were incubated in 0.1% Triton X-100
for 8 min and then washed twice in PBS for 5 min. In situ labeling
of apoptosis-induced DNA strand breaks (TUNEL assay) was
performed using the In Situ Cell Death Detection Kit (Roche,
Switzerland).
2.11. Western blot analysis
Total protein extracted from liver tissue was quantiﬁed using the
BCA Protein Assay Kit (Applygen Technologies Inc. Beijing,
China). Proteins were resolved by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and then transferred to poly-
vinylidene ﬂuoride membranes. The membranes were incubated
sequentially with appropriate primary antibodies and secondary
antibodies. Immune complexes were visualized by super ECL
detection reagent (Applygen, Beijing, China) and band intensities
were determined using the Gel-Pro Analyzer 4.0 software (Media
Cybernetics, USA). Primary antibodies against the following
proteins were used: β-actin, GAPDH, BCL-2, BAX, and cyto-
chrome c (Santa Cruz Biotechnology Inc., USA), and Caspase 3
(Cell Signaling Technology, USA).
2.12. Statistical analysis
All data were expressed as the mean 7 standard deviation (SD).
Differences between groups were assessed using Student's t-test. P
values less than 0.05 were considered statistically signiﬁcant.3. Results
3.1. Induction of chronic immune liver ﬁbrosis in a rat model
via porcine serum administration
At 6 weeks post-PS injection, the HA and PIIINP levels in the
treated group were signiﬁcantly increased as compared to those in
the control group, and continued to increase thereafter. The hepatic
Hyp levels also increased between 6 and 11 weeks post-porcinePlease cite this article as: Li Fangfang, et al. Establishment of a new acute-on
//dx.doi.org/10.1016/j.apsb.2016.09.003serum injection (Fig. 1a). Ultrasound imaging is a popular and
noninvasive tool that is frequently used to diagnose liver diseases.
As shown in Fig. 1b, liver surfaces in the control group showed
smooth, thin and regular hyperechogenic features. At 6 weeks
post-PS injection, however, the liver surfaces showed irregularities
and increased echo intensities. At 8–11 weeks post-treatment, the
liver surfaces demonstrated irregular, spotty surfaces and severely
coarse echoes, indicating that the rats injected with porcine serum
had developed ﬁbrosis. The histopathological changes in the liver
induced by porcine serum are shown in Fig. 1c. The structures of
the control-group livers were clear, with consistent hepatocyte
sizes and no denaturation or necrosis observed. At 6 weeks post-
porcine serum treatment, the livers showed portal inﬂammation
and ballooning degeneration of hepatocytes, representing an early
stage of hepatic ﬁbrosis. At 8 weeks post-porcine serum injection,
the liver tissues showed ﬁbrous tissue hyperplasia, bile duct
proliferation, and inﬂammatory cell inﬁltration. At 10 weeks
post-porcine serum injection, the liver tissues revealed pseudolo-
bule formations and ﬁbrotic septum formation.3.2. Acute liver failure induced by D-gal/LPS treatment via liver
cirrhosis
The ﬁbrotic/cirrhotic rats generated by porcine serum were
injected D-gal and LPS to induce ACLF. The survival times of
ACLF rats are shown in Fig. 2a. Only one rat died within 7.5 h,
most rats died within 13 h, and the mortality was 80% within 48 h.
No rats with cirrhosis died throughout the experiment.
ALT and AST are classical biomarkers of liver injury.
Compared to the group before D-gal/LPS induction (0 h, cirrhosis
rats), the serum levels of ALT and AST markedly increased at 4 h
after induction by D-gal/LPS, whereas the levels signiﬁcantly
decreased at 8 h and 12 h post-treatment. The levels of TBiL,
DBiL and TBA increased substantially at 4 h and peaked at 12 h
post-treatment (Fig. 2b).
Prothrombin time (PT), i.e., the time for the plasma clotting, is
also used to determine liver function, as liver functional abnorm-
alities result in deﬁciencies of coagulation factors. There were no
rats whose PT exceeded 80 s in the normal rat and cirrhotic
groups, with the mean PT being 17 and 21 s respectively. The
clotting time markedly increased at 4 h and at 8–12 h post-
induction by D-gal/LPS (Fig. 2c). At 8–12 h post-induction, the
clotting times of ACLF rats were all longer than 80 s.
The levels of the pro-inﬂammatory cytokines TNF-α and IL-6
are shown in Fig. 2d. Our results demonstrated that normal rats
and cirrhotic rats showed very low TNF-α and IL-6 production.
After induction by D-gal/LPS, the serum levels TNF-α and IL-6
increased signiﬁcantly compared to normal rats and cirrhotic rats.
As shown in Fig. 2e, no signiﬁcant differences were observed in
plasma ammonia levels between the control and cirrhotic groups.
After D-gal/LPS injection, the level of plasma ammonia signiﬁ-
cantly increased at 8 h and 12 h post-treatment compared to those
measured in the control and cirrhotic groups.
The histological features in the livers of control animals
revealed a normal liver lobular architecture and cell structure
(Fig. 2f). At 4 h post-treatment of D-gal/LPS, ballooning degen-
eration of hepatocytes was found, and some areas of necrosis were
observed. At 12 h post- treatment of D-gal/LPS, liver cells showed
obvious necrosis.-chronic liver failure model. Acta Pharmaceutica Sinica B (2016), http:
Fangfang Li et al.43.3. Severe hepatocyte apoptosis induced by combined D-gal/
LPS treatment in ACLF rats
Hepatic levels of apoptosis-related proteins were detected by
Western blot analysis (Fig. 3a–d). The results showed marked
increases in the expression of BAX, while that of BCL-2 decreased
markedly. The expression of cytochrome c peaked at 8 h, but
deceased at 12 h post-treatment. The expression of cleaved caspase-3
peaked 4 h post-treatment of D-gal/LPS and decreased subsequently.Figure 1 Rats were injected with porcine serum for 11 weeks. (a) Change
concentrations (n¼5). (b) Ultrasound image of the livers in rats injected wi
formation of liver ﬁbrosis induced by porcine serum in rats (200 ). ***P
Please cite this article as: Li Fangfang, et al. Establishment of a new acute-on
//dx.doi.org/10.1016/j.apsb.2016.09.003TUNEL assay results are shown in Fig. 3e. Apoptosis was low
in the control group. Compared to the control group, a small
number of hepatocytes showed apoptosis in the ACLF group
before D-gal/LPS induction (0 h). However, apoptosis increased
markedly over time. Twelve hours after D-gal/LPS treatment,
numerous TUNEL-positive cells were observed in the outer
nuclear layer, suggesting dramatic cell death and tissue damage.s in hydroxyproline, hyaluronic acid and N-procollagen type III peptide
th porcine serum (transverse section). (c) H&E staining to illustrate the
o 0.001 compared with the control group.
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ACLF is a severe, life-threatening condition found in patients
with previously diagnosed or undiagnosed chronic liver disease
who have an acute deterioration of liver function and anFigure 2 Rats were subjected to D-gal/LPS injection after porcine seru
(b) Changes in serum biochemical indices after D-gal/LPS treatment in
treatment with D-gal/LPS in ACLF rats (n ¼ 3–5). (d) The plasma level
(e) The plasma levels of ammonia after D-gal/LPS treatment in ACLF rats (
failure induced by D-gal/LPS in ACLF rats (200 ). *Po 0.05, **Po 0.01
P o 0.001 compared with the ACLF animals before D-gal/LPS injection
Please cite this article as: Li Fangfang, et al. Establishment of a new acute-on
//dx.doi.org/10.1016/j.apsb.2016.09.003increased risk of multi-organ failure and death over a short
period, following a precipitating event such as liver injury or
infection2,10. The mechanism whereby patients with cirrhosis
experience rapid liver deterioration, with acutely worsening liver
functions following a superimposed inﬂammatory insult remainsm injection for 11 weeks. (a) Survival rates of ACLF rats (n¼10).
ACLF rats (n¼3–5). (c) Prothrombin time in ﬁbrotic rats following
s of TNF-α and IL-6 after D-gal/LPS treatment in ACLF rats (n¼5).
n¼5). (f) H&E staining was performed to evaluate the effects of liver
, ***Po 0.001 compared with the control group. Po 0.05, Po 0.01,
(0 h).
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Figure 3 Expression of the mitochondrial apoptosis pathway–related protein in the ACLF rat model using Western blot analysis: (a) BCL-2;
(b) BAX; (c) cytochrome c; (d) cleaved caspase-3; and (e) Terminal deoxynucleotidyl-transferase dUTP nick-end labeling (TUNEL) assays
performed to evaluate apoptosis after D-gal/LPS treatment in ACLF rats (400 ). *Po 0.05, **Po 0.01, ***Po 0.001 compared with the control
group; P o 0.05, P o 0.01, P o 0.001 compared with the ACLF animals before D-gal/LPS injection (0 h).
Fangfang Li et al.6
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from applicable animal models simulating this pathophysiologi-
cal process. Therefore, developing an ACLF model that can
mimic these processes would aid in understanding the underlying
mechanism of hepatic damage during ACLF development, which
is necessary for generating novel drugs to treat such a devastat-
ing disease.
In this study, we developed a new ACLF model that mimics
human ACLF as observed in clinical and laboratory settings, and
which represents an improvement over existing animal models.
According to the “two hit” theory11, ACLF is induced by D-gal/LPS
injection following liver ﬁbrosis/cirrhosis induced by PS adminis-
tration. Liver ﬁbrosis induced by PS injection has been widely used
in studying liver ﬁbrosis12,13. Compared to the HSA-induced liver
ﬁbrosis model, our model offers an advantage in terms of simple
operation. In addition, during the ﬁbrosis-induction period, no
animal died, while the HSA-induced model shows a relatively high
mortality of 23%14. Our laboratory previously used HSA to
establish a liver ﬁbrosis model and the death rate was 30% (data
not shown), which is consistent with literature reports. BDL and
CCl4 models are not consistent with the pathogenesis of ACLF.
Moreover, the surgery required for BDL is complex, and the model
is not stable, while our method serves as a stable, repeatable model
and is similar to pathogenesis of ACLF in clinical settings. In the
acute deterioration phase, D-gal/LPS was administered to exacerbate
the pathophysiological processes of ACLF. LPS, a critical compo-
nent of the cell membrane of Gram-negative bacteria, could activate
kupffer cells via toll-like receptor 4 (TLR4)-mediated mitogen-
activated protein kinases (MAPK) and nuclear factor-kappa B
(NF-κB) signal pathways, and stimulate the production and release
of inﬂammatory factors including TNF-α which will induce
apoptosis and necrosis of hepatocytes15. D-Gal is an amino sugar
that is selectively metabolized by hepatocytes, and which induces
liver damage by depletion of the uridine triphosphate pool and
thereby inhibits protein synthesis. With combined exposure to D-gal
and LPS, D-gal speciﬁcally sensitizes the liver towards the cytotoxic
effects of LPS, promoting the development of acute liver injury and
possible death16. Hence, combined administration of D-gal/LPS has
been widely used as to mimic the sequence of events in human
hepatitis.
In our current animal model, we demonstrate that liver ﬁbrosis/
early-stage cirrhosis is induced following PS challenge, which is
supported by the ﬁnding that the levels of HA and PIIINP increased
substantially, and by the ultrasonic-testing and liver-histology
results. Subsequent D-gal/LPS treatment caused acute focal necrosis,
intermittent necrosis within 4 h, and sub-massive hepatic necrosis
within 12 h. These observations were supported by the ﬁndings that
levels of ALT and AST increased signiﬁcantly and decreased
afterwards, and that TBiL, DBiL, and TBA levels increased
markedly. Furthermore, a high rate of mortality was observed
within a short period following D-gal/LPS treatment, starting after
7.5 h and reaching 80% at 48 h, suggesting that our current model
accurately reﬂects the clinical manifestations of ACLF.
Serum biochemical constituents, such as ALT, AST, TBiL,
DBiL and TBA, are widely used to monitor liver functions in
medical practice. ALT and AST are released into the bloodstream
when the liver is damaged or diseased. Bilirubin is a breakdown
product of hemoglobin. TBiL and DBiL are usually measured to
screen for or monitor jaundice caused by liver or gall bladder
dysfunction17. TBA is an exclusive index of liver function. The
speciﬁcity, sensitivity, and stability of TBA measurements renderPlease cite this article as: Li Fangfang, et al. Establishment of a new acute-on
//dx.doi.org/10.1016/j.apsb.2016.09.003it (for many hepatobiliary disorders) superior to conventional liver-
function examinations18. In our current study, a signiﬁcant change
in the activities of serum enzymes and constituents was observed.
At 4 h post-administration of D-gal/LPS, the levels of ALT, AST,
TBiL, DBiL and TBA increased markedly, whereas at 8 h, the
levels of ALT and AST decreased, and the level of TBiL, DBiL
and TBA continuously increased. These data indicate the induction
of sub-massive hepatic necrosis, which is consistent with the
pathogenic processes of ACLF that are observed clinically.
In the clinic, ACLF patients are also found to have coagulation
disorders. The liver plays an important role in hemostasis because
many of the proteins involved in coagulation, antithrombosis, and
ﬁbrinolytic systems are synthesized in the liver. Thus, it is easy to
understand how advanced liver diseases can disrupt hemostatic
functions19,20. In this study, prothrombin time in ACLF markedly
increased after acute D-gal/LPS treatment. We also found increased
plasma ammonia levels in ACLF rats. These two results are
consistent with clinical research21.
The main pathological feature of ACLF is necrosis of numerous
liver cells accompanied with inﬂammatory cell inﬁltration as the
basis for chronic liver failure. We also observed a signiﬁcant
increase in the serum levels of TNF-α and IL-6 in ACLF rats,
which are the important inﬂammatory cytokines of liver failure9.
Given that liver cell apoptosis and necrosis may relate to increased
TNF-α and IL-6 production, this further indicates that their livers
were in an inﬂammatory condition.
TUNEL assay and histological analyses of liver samples were
performed to further evaluate the features of the new ACLF model.
Histopathological ﬁndings showed that ballooning degeneration of
hepatocytes and false liver acini developed at 4 h and the degree of
inﬂammation and necrosis was aggravated at 8 h following the
D-gal/LPS attack. From the pathophysiological point of view, our
current model may closely mimic the symptoms found in ACLF
patients with hepatitis B infection. The TUNEL assay results also
revealed that numerous hepatocytes underwent apoptosis over
time, which is consistent with the histopathology results.
Apoptosis is a cell-suicide mechanism that enables multicellular
organisms to maintain homeostasis and eliminate individual cells
that threaten the organism's survival. Depending on the type of
stimulus, apoptosis can be propagated by an extrinsic pathway or
intrinsic pathway. It is well known that BCL-2 is an apoptosis
inhibitor and that proteins of the BCL-2 family constitute an
important control mechanism in regulating apoptosis22. BAX is a
pro-apoptotic protein that functions by competing with BCL-2 in
cells. A change in the BAX/BCL-2 ratio alters the susceptibility of
cells to apoptosis23. Caspases are intracellular cysteine proteases
that are important components in classical apoptosis. Caspase
activation occurs in response to various types of mitochondrial
damage and pro-apoptotic stimuli which cause cytochrome c
release into the cytosol. Cytochrome c in turn activates caspase
proteins24. We observed a marked increase in BAX expression,
whereas expression of BCL-2 decreased markedly. Cleaved
caspase-3 and cytochrome c were also overexpressed after D-gal/
LPS administration for 4 h and 8 h. Our results suggest that the
intrinsic apoptosis pathway is involved in the development of
ACLF. The role of the extrinsic pathway remains to be elucidated.
During this study, we observed that expression of proteins
decreased after 12 h following the D-gal/LPS attack, which may
be related to protein synthesis dysfunction in hepatocytes. In
summary, we established a new rat model of ACLF which is
useful and stable. Such a model enables investigation of the-chronic liver failure model. Acta Pharmaceutica Sinica B (2016), http:
Fangfang Li et al.8pathophysiology of ACLF and evaluation of the efﬁcacy of novel
drugs. Although our model has advantages compared to the
current models, it does not mimic fully the pathogenesis of ACLF,
and further exploration is needed.
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